入院血糖与急性缺血性卒中动脉内治疗效果的交互作用
结果显示,高血糖(>7.8 mmol/L)或入院血糖水平与治疗对90天改良Rankin量表评分及症状性颅内出血的交互作用均不显著(P=0.67和P=0.87;出血P=0.39)。结论为未发现入院血糖对动脉内治疗效果的效应修饰证据。
要点
- 入院高血糖未显著修饰动脉内治疗对90天功能结局的效应(交互P=0.67)。
- 入院血糖水平与治疗对功能结局的交互作用亦不显著(P=0.87)。
- 高血糖或血糖水平与症状性颅内出血的交互作用均不显著(P=0.39)。
核心结论
- 在急性缺血性卒中患者中,未发现入院血糖对动脉内治疗效果的效应修饰证据。
研究设计与样本
- 高血糖定义为入院血清血糖>7.8 mmol/L,主要结局为90天改良Rankin量表评分偏移的调整共同比值比。
主要发现
- 入院平均血清血糖为7.2 mmol/L(SD 2.2)。
- 高血糖或入院血糖水平与治疗对改良Rankin量表评分的交互作用均不显著(P=0.67和P=0.87)。
- 高血糖或入院血糖水平与症状性颅内出血的交互作用均不显著(P=0.39和P=0.39)。
关键数值与推荐
- 高血糖定义:入院血清血糖>7.8 mmol/L。
- 主要结局:90天改良Rankin量表评分偏移的调整共同比值比,采用序贯逻辑回归估计。
- 交互作用检验采用乘法交互因子并调整预后变量。
临床怎么用
- 对于急性缺血性卒中拟行动脉内治疗的患者,入院血糖水平不应作为改变治疗决策的效应修饰因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Hyperglycemia on admission is common after ischemic stroke. It is associated with unfavorable outcome after treatment with intravenous thrombolysis and after intra-arterial treatment. Whether hyperglycemia influences the effect of reperfusion treatment is unknown. We assessed whether increased admission serum glucose modifies the effect of intra-arterial treatment in patients with acute ischemic stroke. METHODS: We used data from the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Hyperglycemia was defined as admission serum glucose >7.8 mmol/L. The primary outcome measure was the adjusted common odds ratio for a shift in the direction of a better outcome on the modified Rankin Scale at 90 days, estimated with ordinal logistic regression. Secondary outcome variable was symptomatic intracranial hemorrhage. We assessed treatment effect modification of hyperglycemia and admission serum glucose levels with multiplicative interaction factors and adjusted for prognostic variables. RESULTS: Four hundred eighty-seven patients were included. Mean admission serum glucose was 7.2 mmol/L (SD, 2.2). Fifty-seven of 226 patients (25%) randomized to intra-arterial treatment were hyperglycemic compared with 61 of 261 patients (23%) in the control group. The interaction of either hyperglycemia or admission serum glucose levels and treatment effect on modified Rankin Scale scores was not significant (P=0.67 and P=0.87, respectively). The same applied for occurrence of symptomatic hemorrhage (P=0.39 for hyperglycemia, P=0.39 for admission serum glucose). CONCLUSIONS: We found no evidence for effect modification of intra-arterial treatment by admission serum glucose in patients with acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: www.isrctn.com. Unique identifier: ISRCTN10888758.
引用
- Osei E, den Hertog HM, Berkhemer OA, et al. Admission Glucose and Effect of Intra-Arterial Treatment in Patients With Acute Ischemic Stroke. Stroke. 2017. PMID: 28389610. doi:10.1161/STROKEAHA.116.016071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。